Investment Rating - The report maintains a "Buy" rating for the company, indicating a positive outlook for future performance [5]. Core Views - The company's performance is negatively impacted by declining magnesium prices, with projected revenues of 8.983 billion and 10.110 billion for 2024 and 2025 respectively, representing year-on-year growth of 17.39% and 12.55%. However, net profits are expected to decrease significantly, with a forecast of 1.6 billion and 0.28 billion for the same periods, reflecting a decline of 47.91% and 53.58% [1]. - The magnesium-aluminum price ratio has remained below 1 for nearly 11 months, indicating a growing application space for lightweight materials in the automotive sector. Major automotive manufacturers are increasing their use of magnesium products, with potential usage in vehicles expected to rise significantly in the future [1]. - The company has established a comprehensive supply chain from mining to magnesium alloy production, ensuring raw material supply and cost efficiency. Current production capacities include 100,000 tons of raw magnesium and 200,000 tons of magnesium alloy, with additional capacity expansions planned [3]. Summary by Sections Financial Performance - The company is projected to achieve revenues of 89.83 billion and 20.33 billion in Q1 of 2024 and 2025, with respective year-on-year growth rates of 17.39% and 9.08%. However, net profits are expected to decline to 1.6 billion and 0.28 billion, down 47.91% and 53.58% [1]. - The forecast for net profit for 2025-2026 has been revised downwards to 2.11 billion and 2.83 billion, reflecting a decrease of 64.7% and 68.1% respectively, with a new projection for 2027 at 4.23 billion [3]. Market Trends - The magnesium price has decreased by 17.2% since the beginning of 2024, with the current price at 18,210 yuan per ton [1]. - The magnesium-aluminum price ratio is currently at 0.90, indicating a shift towards magnesium in automotive applications, with significant penetration from companies like Seres and Geely [1]. Industry Position - The company benefits from an integrated layout that includes mining, raw magnesium smelting, and magnesium alloy production, which helps in securing raw material supply and reducing production costs [3]. - The company has significant resource reserves, with subsidiaries holding substantial quantities of dolomite resources, ensuring long-term supply stability [3].

美欧达成贸易协议 欧元逢低吸纳 ---- 2025 年 7 月 30 日大公報 https://www.takungpao.com/finance/236135/2025/0730/1108140.html ...

Investment Rating - The report maintains a "Buy" rating for both A-shares and H-shares of the company [5][7]. Core Insights - The company reported significant revenue growth of 20.64% year-over-year, reaching 20.799 billion yuan, and a net profit increase of 101.92%, amounting to 8.561 billion yuan in the first half of 2025 [2][3]. - The strong performance is attributed to the focus on the CRDMO business model, improved production efficiency, and a substantial increase in orders, which reached 56.69 billion yuan, up 37.2% year-over-year [3][4]. Summary by Sections Financial Performance - In Q2 2025, the company achieved revenue of 11.14 billion yuan, a year-over-year increase of 20.37%, and a net profit of 4.89 billion yuan, reflecting a 112.78% increase [2]. - The non-IFRS gross margin improved to 44.5%, an increase of 4.7 percentage points year-over-year [3]. Business Segments - The chemical business generated revenue of 16.3 billion yuan in the first half of 2025, a significant growth of 33.5% [4]. - The TIDES business showed exceptional performance, with revenue reaching 5.03 billion yuan, a year-over-year increase of 141.6% [4]. Profit Forecast and Valuation - The profit forecasts for 2025-2027 have been revised upwards to 15.14 billion yuan, 15.54 billion yuan, and 18.02 billion yuan, representing increases of 37.9%, 24.1%, and 27.3% respectively [5]. - The corresponding P/E ratios for A-shares are projected to be 19, 18, and 16 for the years 2025, 2026, and 2027 [5].

Core Insights - The report highlights a bullish outlook for the A-share and Hong Kong stock markets, with specific stock recommendations for August 2025 [2] - The AI computing demand in the US is expanding into emerging markets, driven by reduced costs of large models, indicating a significant market opportunity for AI applications [3] - The real estate sector has outperformed the market recently, with notable gains in leading companies, suggesting a focus on quality stocks for potential alpha opportunities [4] - The petrochemical industry is expected to benefit from supply-side reforms and the exit of outdated facilities, leading to an improved market structure [5] - The company, Adebiotech, reported strong financial performance in H1 2025, with significant growth in revenue and net profit, indicating a positive trajectory for future earnings [6] Summary by Sections A-Share and Hong Kong Stock Market - The A-share market saw a 7.8% increase from July 1 to July 25, outperforming the CSI 300 index by 2.93 percentage points [4] - Recommended stocks include Dongfang Caifu, Hainan Huatie, Huayou Cobalt, and others for A-shares, and China Life, Xinhua Insurance, Tencent, and Alibaba for Hong Kong stocks [2] AI Industry - The demand for AI computing in the US is growing, particularly in IT operations, cybersecurity, and databases, with a favorable long-term outlook due to a relaxed financing environment and regulatory conditions [3] Real Estate Sector - Leading real estate companies such as New Town Holdings and China Jinmao have shown significant stock price increases, with recommendations to focus on these quality leaders for investment [4] Petrochemical Industry - The report suggests that the petrochemical sector is poised for recovery as outdated production facilities are phased out, with key companies like Tongkun and Hengli Petrochemical recommended for investment [5] Company Performance - Adebiotech achieved a revenue of 579 million yuan in H1 2025, a year-on-year increase of 6.69%, and a net profit of 189 million yuan, reflecting a substantial growth of 31.41% [6] - Future net profit projections for Adebiotech are 343 million, 380 million, and 427 million yuan for 2025, 2026, and 2027 respectively, with a current PE ratio forecasted at 28, 25, and 23 times [6]

Investment Rating - The report maintains an "Overweight" rating for the petrochemical and chemical fiber industry [1] Core Insights - The report highlights that the supply-side clearing pattern is improving, and the industry is awaiting a recovery in prosperity [1] - The report emphasizes the ongoing elimination and upgrading of outdated chemical facilities, which is expected to stabilize the supply side of the industry [4] - The polyester filament industry is experiencing a continuous increase in concentration, with leading companies likely to benefit from the recovery in industry prosperity [5][7] Summary by Sections Industry Overview - The chemical industry is undergoing a phase of eliminating outdated facilities, with a focus on safety and efficiency improvements. A plan has been issued for the period from 2024 to 2029 to phase out non-compliant production facilities and upgrade existing ones [4] - The domestic refining capacity is expected to be maintained at around 1 billion tons, with a target utilization rate of over 80% for major products by 2025 [4] Polyester Filament Sector - The domestic polyester filament capacity has grown from 33.28 million tons in 2019 to 43.16 million tons in 2023, with an annual growth rate of 5%. The growth rate is expected to slow down significantly due to high oil prices and weakened supply-demand dynamics [5] - The industry is shifting from extensive expansion to refined operations, with a focus on high-value-added products, which is expected to enhance the market competitiveness of leading companies [5][7] Investment Recommendations - The report suggests focusing on leading companies in the "refining-chemical fiber" sector, including Tongkun Co., Ltd., Xinfengming Group, Hengli Petrochemical, Rongsheng Petrochemical, Hengyi Petrochemical, and Dongfang Shenghong, as they are expected to benefit from the ongoing industry recovery [8]

Investment Rating - The report maintains a "Buy" rating for the company [6]. Core Insights - The company reported strong performance in H1 2025, with revenue of 579 million yuan, a year-on-year increase of 6.69%, and a net profit attributable to shareholders of 189 million yuan, up 31.41% year-on-year [1][2]. - The core business of testing reagents generated revenue of 483 million yuan, reflecting a growth of 7.93% and accounting for 83.4% of total revenue, with a gross margin of 90.72% [2]. - The company is expanding its international presence, with significant progress in product registration and market access in regions such as Southeast Asia, the Middle East, and Latin America [3]. Summary by Sections Financial Performance - In H1 2025, the company achieved a revenue of 579 million yuan, with a net profit of 189 million yuan, and a net profit excluding non-recurring items of 185 million yuan, marking a growth of 39.97% [1][2]. - The revenue from domestic sales was 442 million yuan, up 7.11%, while international sales reached 137 million yuan, growing by 5.36% [2]. Product Development - The company invested 90.5 million yuan in R&D, representing 15.63% of its revenue, and received two new Class III medical device registrations, bringing the total to 32 [3]. - Five products are currently under review, with three included in innovation or priority approval processes [3]. Profit Forecast and Valuation - The profit forecast for 2025-2026 has been revised upwards to 343 million yuan and 380 million yuan, respectively, reflecting an increase of 11.2% and 4.7% from previous estimates [4]. - The current price corresponds to a PE ratio of 28 for 2025, 25 for 2026, and 23 for 2027 [4].

Group 1 - The A-share and Hong Kong stock markets showed signs of recovery in July, with major indices generally rising, driven by improved market sentiment and policy catalysts. The ChiNext index had the highest increase of 8.7%, while the Shanghai Composite Index had the smallest increase of 3.1% [1][8] - The steel, construction materials, and non-ferrous metals sectors performed well due to ongoing anti-involution policies and infrastructure projects like the Yajiang Hydropower Station [1][8] - The Hong Kong stock market experienced a steady upward trend, with the Hang Seng Technology Index rising by 7.1% and the Hang Seng Index by 5.5% as of July 25, 2025 [1][10] Group 2 - The A-share market is expected to reach new highs in the second half of the year, transitioning from policy-driven to fundamentals and liquidity-driven growth, with potential to surpass the peak of the second half of 2024 [2][12] - Focus on sectors benefiting from anti-involution policies, including coal, steel, photovoltaic, and construction materials, as well as opportunities in electronics and machinery equipment [2][13] - The market is anticipated to exhibit a "rotation and rebound" characteristic, with attention on industries that have lagged behind but have shown strong historical performance [2][13] Group 3 - The Hang Seng Index has surpassed previous highs and is expected to continue its upward trend, supported by strong profitability in the Hong Kong market and low valuations in sectors like internet, new consumption, and innovative pharmaceuticals [3][19] - The "dumbbell" strategy is recommended, focusing on technology growth and high dividend yield sectors, including telecommunications, utilities, and banking [3][19] - Key stocks for August 2025 in the A-share market include Dongfang Caifu, Hainan Huatie, and Huayou Cobalt, while the Hong Kong stock recommendations include China Life, Xinhua Insurance, and Tencent Holdings [3][24][28]

2025 年 7 月 29 日 行业研究 《价格法》修正草案征求意见，反内卷政策持续深化落实 ——建材、建筑及基建公募 REITs 周报（7 月 19 日-7 月 25 日） 要点 《价格法》修正草案征求意见，反内卷相关政策持续深化落实。24 年 7 月中央 政治局会议首次提出防止"内卷式"恶性竞争以来，相关政策持续深化落实。24 年 12 月中央经济工作会议亦提出综合整治"内卷式"竞争，规范地方政府和企 业行为；25 年 3 月政府工作报告指明要综合整治"内卷式"竞争；7 月 1 日中 财委第六次会议再次强调，依法依规治理企业低价无序竞争，引导企业提升产品 品质，推动落后产能有效退出；在 7 月 16 日-17 日中央企业负责人研讨班上， 国资委提出国资央企要超越内卷竞争维护产业价值；7 月 18 日国新办新闻发布 会上，工信部表示，近期将陆续发布新一轮钢铁、有色金属、石化、建材等十大 重点行业稳增长具体工作方案，推动重点行业着力调结构、优供给、淘汰落后产 能；在 7 月 23 日-24 日地方国资委负责人研讨班上，国资委强调要带头抵制"内 卷式"竞争，加强重组整合；7 月 24 日《中华人民共和国价格法修 ...

Investment Rating - The report maintains a "Buy" rating for key companies in the real estate development sector, including Poly Developments, China Merchants Shekou, and Binjiang Group, while also giving a "Buy" rating to China Overseas Development, China Resources Land, and China Jinmao in the H-share sector [37][71]. Core Insights - The real estate sector has shown resilience, with the real estate (Shenwan) index rising by 7.8% from July 1 to July 25, 2025, outperforming the CSI 300 index by 2.93 percentage points [29][37]. - The report highlights a structural alpha opportunity in the real estate sector, particularly for leading companies with strong brand recognition and product reputation, despite a weak beta performance overall [4][65]. - The report emphasizes the importance of urban renewal and structural optimization in high-capacity core cities, which are expected to benefit from ongoing real estate policies [70][71]. Summary by Sections Real Estate Development Sector Valuation and Key Companies - As of July 25, 2025, the real estate (Shenwan) price-to-earnings (P/E) ratio is 42.93, with a historical percentile of 99.45% [11][20]. - The top-performing A-share real estate companies from July 1 to July 25, 2025, include New Town Holdings (+12.2%), China Merchants Shekou (+9.3%), and JinDi Group (+7.4%) [29][31]. Property Services Sector Valuation and Key Companies - The real estate services (Shenwan) P/E ratio is 46.73, with a historical percentile of 86.21% as of July 25, 2025 [2][40]. - The top-performing A-share property service companies during the same period are TeFa Service (+10.4%), World Union (+9.2%), and Ningbo Fuda (+5.9%) [51][55]. Public Fund Holdings in Real Estate Sector - As of the end of Q2 2025, public funds held a total market value of approximately 484.4 billion yuan in real estate stocks, representing a decrease from 548.4 billion yuan at the end of Q1 2025 [3][63]. Market Trends and Sales Performance - In the first half of 2025, the sales amount for commodity residential properties in major cities increased by 6.0%, while the overall sales amount for the top 100 real estate companies decreased by 11.4% [4][66]. - The report notes a significant increase in land transaction prices and areas in key cities, indicating a potential recovery in the real estate market [67][70]. Investment Recommendations - The report suggests focusing on three main lines for investment: stable leading companies with high product reputation, companies with rich existing resources, and the long-term growth potential of the property services sector [71][70].

Group 1: Agricultural Chemicals Industry - The China Pesticide Industry Association has initiated a "Correcting Wind and Treating Volume" action, which is expected to enhance the industry's prosperity [1] - Recommended companies in the agricultural chemicals sector include: raw materials - Yangnong Chemical, Lier Chemical, Xingfa Group, Xin'an Chemical, Jiangshan Chemical, Changqing Chemical, and Xianda Chemical; formulations - Andon Health, Runfeng Co., Guoguang Co., and Nuofushin [1] Group 2: Real Estate Market - As of July 27, 2025, the cumulative transaction of new homes in 20 cities reached 454,000 units, a decrease of 3.8% year-on-year; Beijing saw 24,000 units (-9%), Shanghai 58,000 units (+1%), and Shenzhen 18,000 units (+4%) [2] - The cumulative transaction of second-hand homes in 10 cities reached 451,000 units, an increase of 12.3% year-on-year; Beijing recorded 99,000 units (+12%), Shanghai 147,000 units (+19%), and Shenzhen 40,000 units (+29%) [2] Group 3: Pharmaceutical Company - The company has entered a significant partnership with GSK, granting global exclusive rights for HRS-9821 and up to 11 projects, excluding certain regions, for a payment of $500 million upfront, with potential milestone payments of $12 billion and sales sharing [3] - This collaboration opens up international sales opportunities for the company and strengthens its position as a leader in innovative pharmaceuticals [3] Group 4: Beverage Industry - The company reported a revenue of 10.737 billion yuan for the first half of 2025, representing a year-on-year growth of 36.4%; net profit attributable to shareholders was 2.375 billion yuan, up 37.2% [4] - The forecast for net profit attributable to shareholders for 2025-2027 is adjusted to 4.553 billion, 5.801 billion, and 7 billion yuan, respectively, with corresponding EPS of 8.76, 11.16, and 13.46 yuan [4] - The current stock price corresponds to a PE ratio of 33x for 2025, maintaining a "buy" rating [4]